A Randomized Trial of Rosuvastatin in Elective Angioplasty to Prevent Contrast-induced Nephropathy (CLEAR-CIN).

• Status: Completed
• Trial end date: 2013-12-01
• Target enrollment: 0
• Participant gender: All

Summary

The investigators analyzed the HMG-CoA reductase inhibitor, rosuvastatin, for the prevention of contrast-medium-induced nephropathy in patients undergoing primary angioplasty.

• Phase: Phase 4
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: University of Sao Paulo
• Collaborator: Instituto Dante Pazzanese de Cardiologia
• Treatments: Rosuvastatin Calcium

Criteria

Inclusion Criteria:

• chronic statin use

• positive stress test findings (electrocardiography, nuclear imaging, or stress echocardiography

• elective angioplasty.

Exclusion Criteria:

• non-statin therapy

• any presentation of ACS within 24 hours before the time of randomization

• current use of potent CYP3A4 inhibitors, including azole antifungals, protease inhibitors, macrolide antibiotics, and cyclosporine

• renal replacement therapy, a history of kidney transplant, pregnant and with renal failure (serum creatinine > 3.0 mg/dl).